Janssen files Darzalex Faspro for rare disease light chain amyloidosis
Janssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal disease...
Read moreResearch & Access Updates
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing life-chan...
Read morePomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM):
In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior e...
Read moreMore on ASCO 2020
At the end of May, myeloma researchers would have flocked to Chicago for the 56th Annual Meeting of the A...
Read moreJanssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved...
Read moreSeroprevalence Studies May Underestimate Immunity To The Coronavirus
Globally, there are more than 18 million confirmed novel coronavirus infections. A question many have is...
Read more